CL2004001697A1 - Uso de un material de proteina monocelular para la elaboracion de una preparacion farmaceutica o nutricional, para tratar y/o prevenir la ateroesclerosis, cardiopatias coronarias, estenosis, trombosis, infarto al miocardio, apoplejia y esteatosis hep - Google Patents

Uso de un material de proteina monocelular para la elaboracion de una preparacion farmaceutica o nutricional, para tratar y/o prevenir la ateroesclerosis, cardiopatias coronarias, estenosis, trombosis, infarto al miocardio, apoplejia y esteatosis hep

Info

Publication number
CL2004001697A1
CL2004001697A1 CL200401697A CL2004001697A CL2004001697A1 CL 2004001697 A1 CL2004001697 A1 CL 2004001697A1 CL 200401697 A CL200401697 A CL 200401697A CL 2004001697 A CL2004001697 A CL 2004001697A CL 2004001697 A1 CL2004001697 A1 CL 2004001697A1
Authority
CL
Chile
Prior art keywords
preparation
pharmaceutical
cardiopatias
apoplejis
miocardio
Prior art date
Application number
CL200401697A
Other languages
English (en)
Inventor
Berge Gunnar Kleppe Rolf
Original Assignee
Thia Medica As Berge Biomed As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As Berge Biomed As filed Critical Thia Medica As Berge Biomed As
Publication of CL2004001697A1 publication Critical patent/CL2004001697A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Animal Husbandry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE RELACIONA CON EL USO DE BIOMASA DE CELULAS MICROBIANAS (SCP). EL MATERIAL SCP BAJA LA CONCENTRACION DE COLESTEROL Y TRIGLICERIDOS EN EL PLASMA DE UN SER VIVO. SCP TAMBIEN INDUCE A CAMBIOS EN EL PATRON DE ACIDDO GRASO Y BAJA LA CONCENTRACION DE HOMOCISTEINA. UNA REALIZACION PREFERIDA DE LA INVENCION SE RELACIONA CON EL USO DE SCP COMO UN ANTI-ATEROGENICO Y AGENTE PROTECTOR CARDIACO, CADA UNO DE LOS CUALES SE ADMINISTRAN COMO UNA COMPOSICION FARMACEUTICA O UNA COMPOSICION NUTRICIONAL, POR EJEMPLO COMO COMIDA FUNCIONAL.
CL200401697A 2003-07-04 2004-07-02 Uso de un material de proteina monocelular para la elaboracion de una preparacion farmaceutica o nutricional, para tratar y/o prevenir la ateroesclerosis, cardiopatias coronarias, estenosis, trombosis, infarto al miocardio, apoplejia y esteatosis hep CL2004001697A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20033082A NO319551B1 (no) 2003-07-04 2003-07-04 Proteinmateriale fra enkeltceller

Publications (1)

Publication Number Publication Date
CL2004001697A1 true CL2004001697A1 (es) 2005-05-06

Family

ID=27800774

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401697A CL2004001697A1 (es) 2003-07-04 2004-07-02 Uso de un material de proteina monocelular para la elaboracion de una preparacion farmaceutica o nutricional, para tratar y/o prevenir la ateroesclerosis, cardiopatias coronarias, estenosis, trombosis, infarto al miocardio, apoplejia y esteatosis hep

Country Status (9)

Country Link
US (1) US20070141083A1 (es)
JP (1) JP2007527385A (es)
KR (1) KR20060079789A (es)
CN (1) CN1845749B (es)
CA (1) CA2542401A1 (es)
CL (1) CL2004001697A1 (es)
NO (1) NO319551B1 (es)
PE (1) PE20050993A1 (es)
WO (1) WO2005002606A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553260A (en) 2004-07-19 2010-12-24 Thia Medica As Composition comprising protein material and non-oxidizable fatty acid entities
EP2123171A1 (de) * 2008-05-20 2009-11-25 Otto Thannesberger Futtermischung
EP2427200B1 (en) * 2009-05-08 2014-04-30 Bioprotein AS Feed composition for the treatment or prevention of enteritis in fish
CA2998528A1 (en) 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
WO2018204792A2 (en) * 2017-05-05 2018-11-08 White Dog Labs, Inc. Single cell protein products and an integrated method for the production of ethanol and single cell protein
US10883123B2 (en) 2017-06-09 2021-01-05 White Dog Labs, Inc. Integrated wet-mill method for the production of ethanol and single cell protein
GB201712459D0 (en) 2017-08-02 2017-09-13 Norges Miljø-Og Biovitenskapelige Univ Treatment or prevention of gastrointestinal dysbiosis
RU2681791C1 (ru) * 2018-07-12 2019-03-12 Общество с ограниченной ответственностью "ГИПРОБИОСИНТЕЗ" Биологически активная добавка защитного действия "дримфуд"
CN112326817B (zh) * 2020-10-19 2022-04-22 秦皇岛海关技术中心 一种鉴别茴香蜂蜜的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
GB0003620D0 (en) * 2000-02-16 2000-04-05 Norferm Da Method
JP3784045B2 (ja) * 2000-04-27 2006-06-07 明治乳業株式会社 Ｌｄｌ酸化抑制飲食品及び医薬品
EP1324671A4 (en) * 2000-09-07 2005-09-07 Univ Maryland Biotech Inst USE OF ARACHIDONIC ACID TO STRENGTHEN THE LIFTING OF FISH LARVAES AND THE STOCK OF REPRODUCERS
JP2002212083A (ja) * 2001-01-17 2002-07-31 Yakult Honsha Co Ltd コレステロール低下剤
GB0120047D0 (en) * 2001-08-16 2001-10-10 Norferm Da Product

Also Published As

Publication number Publication date
NO319551B1 (no) 2005-08-29
PE20050993A1 (es) 2005-11-30
US20070141083A1 (en) 2007-06-21
CN1845749B (zh) 2010-04-28
KR20060079789A (ko) 2006-07-06
NO20033082D0 (no) 2003-07-04
WO2005002606A1 (en) 2005-01-13
CA2542401A1 (en) 2005-01-13
NO20033082L (no) 2005-01-05
CN1845749A (zh) 2006-10-11
JP2007527385A (ja) 2007-09-27

Similar Documents

Publication Publication Date Title
CL2004001642A1 (es) Uso de un hidrolizado de proteina de pescado util para elaborar composiciones farmaceuticas y nutricionales, metodo de elaboracion de dicho hidrolizado.
BRPI0416796A (pt) compostos orgánicos
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
ATE554800T1 (de) Medizinische vorrichtungen mit porösen regionen zur kontrollierten aussetzung oder verabreichung therapeutischer wirkstoffe
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
AR033367A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
CU23213A3 (es) Difenilureas sustituidas con omega-carboxiarilo como inhibidores de raf quinasa
BRPI0608297A2 (pt) composições de lipossomos
GEP20094601B (en) Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes
DK1390049T3 (da) Sammensætninger til behandling af dyresygdomme og -syndromer omfattende transferfaktor
BR0009043A (pt) Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
ES2150447T3 (es) Formas purificadas de desoxiribonucleasa.
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
MX2010006436A (es) Derivados peptidos mimeticos de eritropoyetina y sus sales farmaceuticas, su preparacion y usos.
CL2004001697A1 (es) Uso de un material de proteina monocelular para la elaboracion de una preparacion farmaceutica o nutricional, para tratar y/o prevenir la ateroesclerosis, cardiopatias coronarias, estenosis, trombosis, infarto al miocardio, apoplejia y esteatosis hep
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
DE502004011851D1 (de) Caspase 3, 8, 9 oder 10 Inhibitoren in Kombination mit MEK Inhibitoren zur Behandlung von Influenza
EA200602092A1 (ru) Способ и композиция для лечения ринита
WO2006051549A3 (en) Combination therapy associating preferably a ceramide with a cytotoxic drug
BRPI0408299A (pt) inibidores de catepsina s
BRPI0606833A2 (pt) uso de 2, 4-dihidróxi-3-metilbenzoato, medicamento para o tratamento da hiperplasia prostática, carcinoma de próstata ou da atrofia muscular espino-bulbar, 2,4-dihidróxi-3-metilbenzoato, processo para o isolamento do ácido atrárico a partir de um material biológico e processo para a sìntese de derivados do ácido atrárico
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
UY29544A1 (es) Tratamiento de enfermedades usando un sistema mejorado de expresión regulada